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High serum Cyclophilin C levels as 
a risk factor marker for Coronary 
Artery Disease
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Cyclophilins (Cyps) are ubiquitous proteins that belong to the immunophilins family consistently 
associated with inflammatory and cardiovascular diseases. While levels of CypA have been extensively 
studied, less data are available for other Cyps. the purpose of this case-control study was to determine 
the relationship of Cyps (A, B, C and D) with coronary artery disease (CAD) and eight inflammation 
markers. serum levels of Cyps, interleukins and metalloproteinases were measured in serum collected 
from 84 subjects. Participants were divided into two sub-groups based on CAD diagnosis: 40 CAD 
patients and 44 control volunteers. Serum levels of CypA, CypB and CypC, IL-1β and IL-6 were 
significantly higher in CAD patients. Bivariate correlation analysis revealed a significant positive 
correlation between Cyps and several blood and biochemical parameters. When the ability of Cyps levels 
for CAD diagnosis was evaluated, higher sensitivity and selectivity values were obtained with CypC 
(c-statistic 0.891, p < 0.001) indicating that it is a good marker of CAD disease, while less conclusive 
results were obtained with CypA (c-statistic 0.748, p < 0.001) and CypB (c-statistic 0.655, p < 0.014). In 
addition, significant correlations of traditional CAD risk factors and CypC were observed. In summary, 
high levels of CypC are a risk factor for CAD and therefore it can be proposed as a new biomarker for this 
disease.
Coronary artery disease (CAD) is an ischemic heart disease of coronary arteries mainly caused by atherosclerosis. 
The risk of CAD is increased in patients with traditional cardiovascular risk factors such as diabetes mellitus, age, 
tobacco, high blood pressure, chronic kidney disease, high lipid levels, overweight and obesity1–4. In addition, 
there is a higher incidence in mortality when CAD is associated to inflammatory and autoimmune diseases, being 
systemic inflammation a key factor in the development of this disease5. Besides, there is a general agreement of 
the fact that atherosclerosis is an inflammatory disease, and that inflammation plays an important role in the 
atherogenic process. Thus, inflammation contributes to all stages of atherosclerosis, from plaque formation to 
instability and eventual plaque rupture5–8.
Immunophilins are a family of peptidyl-prolyl cis/trans isomerases (PPIases) consistently involved in car-
diovascular diseases9. PPIases include three protein subfamilies, Cyclophilins (Cyps), FK506-binding proteins 
(FKBP) and parvulins. Some of these proteins, namely CypA, CypB, CypD or FKBP51 have been previously asso-
ciated with CAD10–13. Cyps are a highly conserved family of ubiquitous enzymes with at least 17 types. They cata-
lyze cis-trans isomerization of protein peptidyl-prolyl bonds and modulate protein folding and assembly. CypA, 
CypB and CypC are secreted to the extracellular space while CypD is usually localized in the mitochondria9. 
CypA is secreted to the extracellular media after inflammatory stimuli and both intra and extracellular CypA 
are involved in several cardiovascular diseases9,14. Intracellular CypA plays a role in NOX enzyme translocation, 
Janus and ERK1/2 activation, Reactive Oxygen Species (ROS) production and oxidative stress9. CypB is expressed 
at lower levels than CypA and has an important role in redox hemostasis and inflammation with different effects 
depending on intracellular or extracellular localization and in the vascular function9,15. Both, CypA and CypB, are 
ligands of the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) (CD147) receptor16. These proteins 
are constitutively secreted through vesicles by endothelial and vascular smooth muscle cells (VSMC), fibroblasts, 
macrophages and platelets in response to oxidative stress. Moreover, CypA acts as a chemoattractant along with 
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cytokines in inflammatory cells and CypB was also described as a chemotaxis inducer of inflammatory cells into 
damage tissues9. CypC is localized in the kidney and modulates macrophage activation, endotoxin signaling, 
and metalloproteinase-13 expression and it is also involved in macrophages activation and redox homeostasis of 
endoplasmic reticulum together with CypB15,17. The cyclophilin C-associated protein is the endogenous ligand for 
CypC that regulates the response to endotoxins and macrophages activation17. CypD plays a role in the opening 
of mitochondrial permeability transition pore (mPTP), and has been linked to apoptosis, Alzheimer’s disease and 
heart failure12.
While the role, mode of action and localization of CypA in cardiovascular diseases is well documented and it 
has been proposed as a biomarker for CAD, less data are available about other Cyps, in terms of cellular targets 
or extracellular levels, and the relationship of those when other cardiovascular risk factors are present9,14,16,18. 
Besides, as it was mentioned, the relationship of Cyps and inflammation has been extensively discussed. 
Extracellular Cyps levels are considered as an inflammatory response to injury since they are increased in inflam-
matory tissues and body fluids in many acute and chronic inflammatory processes19,20. In addition, Cyps are 
related to redox homeostasis, and redox mediated signaling has an important role in inflammation, atheroscle-
rosis and CAD15,21,22. Taking into account the multiple cross-talks of these enzymes, the aim of this paper was 
to explore the levels of CypA, B, C and D and several inflammatory markers in CAD patients in order to better 
understand and predict this disease.
Results
84 participants (mean age 54.3 ± 1.58, range 26–85 years, 66.7% male) were enrolled in the present study and 
divided into two sub-groups based on CAD diagnosis: 40 CAD patients (35 men and 5 women) and 44 control 
volunteers (CAD free) (22 men and 22 women). The same measurements were done in both populations to 
compare results. First, serum levels of Cyp A, B, C and D were measured (Table 1). Figures 1–4 show the distri-
bution of patients with and without CAD by serum levels of Cyps and the distribution of Cyp levels among the 
groups under study (CAD patients and control volunteers). As it was expected, the levels of CypA, Fig. 1, were 
significantly increased in CAD patients, 7.80 ng/mL ± 1.02 compared with control subjects, 2.44 ng/mL ± 0.46 
(P < 0.001). When CypB levels were compared, as shown in Fig. 2, the values in CAD patients were signifi-
cantly higher than in control participants, 208.83 pg/mL ± 36.18 and 148.69 pg/mL ± 35.34 (P < 0.05), respec-
tively. In the case of CypC, Fig. 3, the levels in CAD patients were significantly higher, 34.28 pg/mL ± 5.77 versus 
9.60 pg/mL ± 1.52 (P < 0.001). However, when CypD levels were measured, Fig. 4, no significant differences were 
observed, 97.68 pg/mL ± 10.69 in CAD patients versus 127.33 pg/mL ± 20.84 in control subjects. Furthermore, 
levels of eight inflammation markers, IFNϒ, IL-1β, IL-2, IL-6, IL-8, TNFα, MMP-2 and MMP-9 were also ana-
lyzed to understand their relationship with immunophilins production and CAD. As Table 1 shows, no signifi-
cant modifications in the levels of these parameters were observed when CAD patients and control participants 
were compared, with three exceptions, IL-1β, IL-6 and MMP-2. IL-6 levels were significantly increased in CAD 
patients, 8.08 pg/mL ± 1.59, with respect to control subjects, 3.82 ± 0.30, (P < 0.05). Also, IL-1β levels were signif-
icantly increased in CAD patients, 3.73 pg/mL ± 0.36, versus 2.71 pg/mL ± 0.17 for control subjects (P < 0.05). On 
the contrary, MMP-2 levels were significantly decreased, from 120.9 ng/mL ± 5.11 in control subjects to 95.43 ng/
mL ± 5.69 in CAD patients (P < 0.001).
At the same time, traditional baseline characteristics as well as laboratory data of participants were collected 
and are shown in Table 2. Results were divided in two populations. As Table 2 shows, a higher percentage of 
patients with CAD were smoker or ex-smoker, with history of cardiac failure and some of them had peripheral 




(n = 40) P Value
CypA (ng/mL) 2.44 ± 0.46 7.80 ± 1.30 <0.001
CypB (pg/mL) 138.55 ± 33.39 208.83 ± 44.76 0.014
CypC (pg/mL) 9.60 ± 1.52 34.28 ± 5.77 <0.001
CypD (pg/mL) 127.33 ± 20.84 97.68 ± 10.69 0.687
IFNϒ (pg/mL) 34.26 ± 2.89 27.43 ± 2.65 0.073
IL-1β (pg/mL) 2.72 ± 0.17 3.73 ± 0.36 0.016
IL-2 (pg/mL) 4.32 ± 0.45 4.97 ± 0.51 0.543
IL-6 (pg/mL) 3.98 ± 0.33 8.08 ± 1.59 0.028
IL-8 (pg/mL) 8.01 ± 0.64 7.02 ± 0.75 0.131
TNFα (pg/mL) 10.34 ± 0.47 9.27 ± 0.64 0.123
MMP-2 (ng/mL) 121.53 ± 5.03 95.43 ± 5.69 <0.001
MMP-9 (ng/mL) 256.85 ± 45.81 221.37 ± 20.44 0.087
Table 1. Human serum levels of Cyclophilins and inflammatory markers in control subjects and coronary 
artery disease patients. Data are shown as average ± SEM. Significance (p < 0.05) comparing CAD patients and 
control subjects. Coronary artery disease (CAD), Cyclophilin A (CypA), Cyclophilin B (CypB), Cyclophilin 
C (CypC), Cyclophilin D (CypD). Interferon ϒ (IFNϒ), interleukin (IL), tumor necrosis factor α (TNFα), 
metalloproteinase (MMP). Student’s T test or Mann-Whitney test were used to perform statistical analysis. 
Significant differences p < 0.05.
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Figure 1. Serum Cyclophilin A (CypA) levels in control subjects (n = 44) and in patients (n = 40) with 
coronary artery disease (CAD). (A) Frequency plot: Data represented as CypA levels (X-axis) versus number 
of subjects (n = 84) (Y-axis). (B) Data are shown as dots of CypA levels in control subjects (control, n = 44) and 
CAD patients (n = 40). (C) Data are shown as box-and-whisker plots of CypA levels in control subjects (n = 44) 
and CAD patients (n = 40). CypA was significantly elevated (***P < 0.001, Mann-Whitney U test) in CAD 
patients compared with controls.
Figure 2. Serum Cyclophilin B (CypB) levels in control subjects (n = 44) and in patients (n = 40) with coronary 
artery disease (CAD). (A) Frequency plot: Data represented as CypB levels (X-axis) versus number of subjects 
(n = 84) (Y-axis). (B) Data are shown as dots of CypB levels in control subjects (control, n = 44) and CAD 
patients (n = 40). (C) Data are shown as box-and-whisker plots of CypB levels in control subjects (n = 44) and 
CAD patients (n = 40). CypB was significantly elevated (**P < 0.01, Mann-Whitney U test) in CAD patients 
compared with controls.
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Figure 3. Serum Cyclophilin C (CypC) levels in control subjects (n = 44) and in patients (n = 40) with 
coronary artery disease (CAD). (A) Frequency plot: Data represented as CypC levels (X-axis) versus number 
of subjects (n = 84) (Y-axis). (B) Data are shown as dots of CypC levels in control subjects (n = 44) and CAD 
patients (n = 40). (C) Data are shown as box-and-whisker plots of CypC levels in control subjects (n = 44) and 
CAD patients (n=40). CypC was significantly elevated (***P < 0.001, Mann-Whitney U test) in CAD patients 
compared with controls.
Figure 4. Serum Cyclophilin D (CypD) levels in control subjects (n = 44) and in patients (n = 40) with 
coronary artery disease (CAD). (A) Frequency plot: Data represented as CypD levels (X-axis) versus number 
of subjects (n = 84) (Y-axis). (B) Data are shown as dots of CypD levels in control subjects (n = 44) and CAD 
patients (n = 40). (C) Data are shown as box-and-whisker plots of CypD levels in control subjects (n = 44) and 
CAD patients (n = 40).
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CAD patients. Besides, clinical parameters as total cholesterol, LDL and HDL cholesterol, triglycerides (TG), 
C-reactive protein (CRP) and alanine aminotransferase (ALT) were also measured. While TG, CRP and ALT 
were significantly increased in CAD patients, cholesterol values were significantly decreased, according to statins 
treatment in this cardiovascular high-risk populations. In the case of blood cell count, white blood cells (WBC), 
neutrophils, monocytes and hemoglobin were significantly increased in CAD patients as well as glucose levels, 
while lymphocytes and platelets were not modified. Significantly more CAD patients were under treatment with 
statins, antiplatelets/anticoagulant, antihypertensives and hypoglycemics.
Bivariate correlation analysis of Cyps and clinical parameters revealed, Table 3, a significant positive corre-
lation between CypC levels and the levels of CypA (p < 0.002), CypB (p < 0.001) and CypD (p < 0.01). In addi-
tion, CypC was positively associated to IL-6, WBC, neutrophils and glucose. Furthermore, CypC was negatively 
associated with MMP-2 and HDL levels. In the case of CypA, there is a significant positive correlation between 
the levels of this immunophilin and IL-1β, TG, ALT, neutrophils and glucose levels, while a negative correlation 
is observed with IL-8, TNFα, MMP-2 and HDL. CypB levels were positively associated with CypD, IL-6 and 
MMP-9 measures and negatively with hemoglobin levels. Finally, CypD serum levels were only positively asso-
ciated with MMP-9 and platelet. No correlations of Cyps levels with IFNϒ, IL-2, total cholesterol, LDL, lympho-
cytes and monocytes were observed. Besides CypA levels were significantly (p < 0.05) elevated in subjects with 
traditional cardiovascular risk factors such as hypertension, dyslipidemia, smoking, gender (male) and age > 50 
years, Fig. 5A. In the case of CypB, Fig. 5B, the levels were significantly elevated in subjects with hypertension 
Control subjects (n = 44) CAD patients (n = 40) P Value
Male (%) 50% 87.5% 0.001
Smoker 2.3% 37.5% <0.001
Ex-smoker 15.9% 27.5% <0.001
Family History of CAD 18.2% 17.5% 0.900
CF History 0.0% 15% 0.009
Peripheral arterial disease 0.0% 7.5% 0.064
Medical history
Hypertension (HTA) 6.8% 47.5% <0.001
Dibetes Mellitus Type 1 0.0% 2.5% <0.05
Dibetes Mellitus Type 2 2.3% 17.5% <0.05
Dyslipidemia (DL) 13.6% 67.5% <0.001
Total Cholesterol (mg/dL) 202.57 ± 1.54 177.05 ± 6.74 0.004
LDL (mg/dL) 122.03 ± 3.90 108.00 ± 5.54 0.071
HDL (mg/dL) 58.00 ± 2.55 36.53 ± 1.29 <0.001
TG (mg/dL) 106.89 ± 6.84 164.00 ± 11.31 <0.001
CRP* (mg/dL) 0.49 ± 0.14 43.45 ± 15.10 <0.001
ALT (U/L) 22.06 ± 2.38 33.32 ± 3.74 0.003
WBC (number/µL) 6632.35 ± 320.45 10383.50 ± 748.25 <0.001
Lymphocytes (number/µL) 2139.39 ± 113,98 1982.50 ± 184.63 0.119
Neutrophils (number/µL) 3757.58 ± 293.36 7462.50 ± 670.15 <0.001
Monocytes (number/µL) 548.48 ± 23.08 730.00 ± 49.90 0.01
Hemoglobine (pg) 13.91 ± 0.23 14.65 ± 0.24 0.028
Platelet (number/µL) 230205.88 ± 8777.89 221925.00 ± 12331.08 0.648
Glucose (mg/dL) 90.23 ± 5.48 110.80 ± 3.16 0.001
Medications
Statins 11.4% 42.5% 0.003
Antiaplatelets/anticoagulant 0.0% 22.5% 0.001
Antihypertensives 9.1% 52.5% <0.001
Hypoglycemics 2.4% 15.0% 0.05
Angiographyc findings
1-vessel disease 0.0% 47.5% N/A
2-vessel disease 0.0% 30.0% N/A
3-vessel disease 0.0% 22.5% N/A
Total Revasc 0.0% 70.0% N/A
Table 2. Baseline clinical characteristics in control subjects and Coronary Artery Disease (CAD) patients. Data 
are shown as average ± SEM. Significance (p < 0.05) comparing CAD patients and control subjects. Cardiac 
failure (CF), low density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG), C-reactive 
protein (CRP), alanine aminotransferase (ALT), white blood cells (WBC). *N = 30. Student’s T test or Mann-
Whitney test were used to perform statistical analysis. Categorical variables were compared using Χ2 test. 
Significant differences p < 0.05.
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(p < 0.01) and gender (male) (p < 0.05). Interesting CypC was significantly elevated (p < 0.002) by the presence 
of all cardiovascular risk factors with the exception of gender, Fig. 5C. Finally, CypD levels were not related to the 
risk factors, Fig. 5D.
Then, to evaluate the sensitivity and selectivity of Cyps values for the diagnosis of CAD, ROC curves were 
calculated on the basis of immunophilin levels, using CAD presence or absence as state variable or specific con-
dition. As Fig. 6 shows, higher sensitivity and selectivity values were obtained with CypC. The AUC (c-statistic) 
calculated was 0.891 showing a significant value (p < 0.001) for CypC as predictor of CAD. For CypA and CypB, 
AUC were also significant, 0.748 and 0.655 respectively while CypD values are not useful to predict CAD. 
Therefore, it can be concluded that CypC is a good marker, CypA is fair as marker while CypB is a poor marker. 
From ROC curves, cut-off points for CAD presence were obtained as a compromise between sensitivity and selec-
tivity. A cut-off for CypA > 8.2 ng/mL provides a specificity of 95.5%, a sensitivity of 32.5%, a positive predictive 
value (VPP) of 86.7%, a negative predictive value (VPN) of 60.9% and statistic power (P) of 65.5%. A cut-off for 
CypB > 204 pg/mL provides a specificity of 77.3%, a sensitivity of 25%, a VPP of 50%, a VPN of 53.1% and P of 
52.4%. In the case of CypC, a cut-off > 17.5 pg/mL provides a specificity of 88.6%, a sensitivity of 70%, a VPP of 
84.8%, a VPN of 76.5% and P of 79.8%. These values were used to evaluate the association between serum Cyps 
levels and traditional risk factors (gender, age, smoke, dyslipidemia and HTA). Each of the known risk factors and 
Cyps were combined in a single logistic-regression model (Table 4). When CypB > 204 pg/mL and CAD corre-
lations were studied (univariable analysis) no significant differences were observed (data not shown), therefore 
this protein was not used for multivariable analysis. However, as Table 4 shows, either traditional risk factors and 
CypA and C are highly related with disease status (OR values between 7 and 18.2 and p > 0.005), with a higher 
relationship in the case of CypC. When multivariable analyses were performed with traditional risk factors, OR 
values were decreased while CI increased, compared to univariable analysis, but still significant. When CypA was 
added to risk factors, both age and CypA lost the correlation with CAD, while the rest of risk factors remained 
highly related with the disease. The inclusion of CypC in multivariable analysis, instead of CypA, resulted in a 
significant improvement of the overall performance of the logistic regression model (Cox-Snell R2 from 0.54 to 
0.596), although CI were also increased, and age and smoking condition lost the correlation with CAD. Finally, 
when both, CypA and CypC, were included in the logistic regression model, R2 was improved to 0.605 as well as 
the CI. In summary, additionally to traditional risk CAD factors, levels of CypC over 17.5 pg/mL or of CypA over 
8.2 ng/mL increase the risk of CAD. Therefore, CypA serum levels but especially the level of CypC can be useful 
biomarkers for CAD.
Discussion
Cyps play a key role in protein folding, repairing damaged proteins, modulation of the immune system, and other 
biological functions, although the role of most of the components of this family is not well known23,24. In addition 
to physiological functions, these proteins have been related with many other processes. In this regard, Cyps have 
been associated to cancer, aging, diabetes mellitus, chronic kidney diseases and neurodegeneration among others. 
Nevertheless, they seem to play a especial, and critical role in cardiovascular diseases9,12. In fact, CypA plasma 
levels have been previously proposed as biomarkers for coronary artery disease having also prognostic impact18,21. 
CypA CypB CypC CypD
CypA 0.339 (p < 0.005)
CypB 0.535 (p < 0.001) 0.389 (p < 0.001)
CypC 0.339 (p < 0.002) 0.535 (p < 0.001) 0.284 (p < 0.01)
CypD 0.389 (p < 0.001) 0.284 (p < 0.01)
IL-1β 0.304 (p < 0.01)
IL-6 0.257 (p < 0.01) 0.302 (p < 0.005)
IL-8 −0.300 (p < 0.005)
TNFα −0.298 (p < 0.005)
MMP-2 −0.270 (p < 0.01) −0.215 (p < 0.05)
MMP-9 0.304 (p < 0.005) 0.378 (p < 0.001)
HDL −0.294 (p < 0.01) −0.466 (p < 0.001)
TG 0.266 (p < 0.05)
CRP 0.409 (p < 0.05) 0.577 (p < 0.005)
ALT 0.332 (p < 0.005)
WBC 0.219 (p < 0.05) 0.310 (p < 0.005)
Neutrophils 0.296 (p < 0.01) 0.379 (p < 0.001)
Hemoglobin −0.238 (p < 0.05)
Platelet 0.262 (p < 0.05)
Glucose 0.363 (p < 0.001) 0.520 (p < 0.001)
Table 3. Correlations between cyclophilins, inflammation markers and clinical parameters. Bivariate analysis, 
N = 84. Spearman coefficient and significance (p < 0.05). Significant differences p < 0.05. Abbreviations as in 
Tables 1 and 2.
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However, the role of the other Cyps and their relationship with CypA is less known. In the present study, we 
describe the serum levels of 4 Cyps and 8 inflammation markers in patients with acute CAD in comparison to 
healthy individuals, in order to clarify their relationship and to know if the less-studied immunophilins have a 
role in this disease.
CypA is released to the extracellular media in response to inflammatory stimuli and it is a critical regulator of 
endothelial cell dysfunction, vascular smooth muscle cells, fibroblast proliferation and cardiac hypertrophy9,12. 
In addition, CypA is involved in atherosclerosis, in oxidative stress, in nitric oxide generation and probably in 
blood pressure regulation9,12. We observed that CypA levels were significantly increased in CAD patients, as it 
was previously described18,21,25. In addition, the levels of CypA were correlated with several clinical parameters 
and with several inflammation markers as IL-1β, IL-8, TNFα, MMP-2, as well as with CRP, a known clinical 
marker of vascular inflammation. The correlation of CypA and CRP was before described and the role of both to 
predict the risk of coronary artery disease, or as markers of proinflammatory status in patients with diabetes was 
hypothesized11,18,21,25. Extracellular CypA has been involved in the production of IL-8, IL-1β, TNFα and MMP-9, 
while MMP-2 was not affected26,27. From our results, including ROC values, the role of CypA as CAD biomarker 
is reinforced although no significant correlation with traditional CAD risk factor was observed, probably due to 
the limited population used.
CypB is also abundant in all tissues but at lower levels than CypA. It has a crucial role against ROS and 
pro-inflammatory stimuli ant to induce chemotaxis of inflammatory cells. In addition, CypB levels were asso-
ciated with the prevalence of metabolic syndrome and it is also related to hypertension, ROS effects in vascular 
function and heart failure9,13,28. In the present study, CypB levels were significantly increased in CAD patients and 
this increase was associated with IL-1β, IL-6, and MMP-9. However, CypB for CAD diagnosis, with a c-statistic 
0.655 seems to be, although significant, a poor marker.
CypC is the less known among the Cyps studied in the present work. It has been mostly described in the kid-
ney, but it was also reported to be localized intracellular and extracellularly19. The physiological or pathological 
role of this protein is still unknown, although it was related to macrophages activation and the levels are increased 
in cerebral tissues after ischemia29. In our study, CypC levels were significantly increased in patients with acute 
Figure 5. Cyclophilin levels and cardiovascular risk factors (hypertension, dyslipidemia, smoking, gender, 
diabetes, age > 50). (A) Cyclophilin A (CypA) levels were significantly increased by the presence of 
hypertension, dyslipidemia, smoking, age of 50 years or older and in men but not by diabetes. (B) Cyclophilin B 
(CypB) levels were significantly increased by the presence of hypertension and in men but not by dyslipidemia, 
smoking, diabetes or age of 50 years or older. (C) Cyclophilin C (CypC) levels were significantly increased by 
the presence of hypertension, dyslipidemia, smoking, diabetes and age of 50 years or older but not by gender 
difference. (D) Cyclophilin D (CypD) levels were not significantly increased by the presence of cardiovascular 
risk factors. Mann-Whitney U Test was used to check statistic significances, N = 84. (***P < 0.001, **P < 0.01, 
*P < 0.05).
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CAD. In fact, the values were three times higher. Interestingly, this protein was significantly associated with 
CypA, CypB and CypD levels as well as with IL-6, a well-known inflammatory marker associated to the rupture 
of the atheroma plaque5,30. CypC has a significant role as CAD marker when values are up to 17.5 pg/mL with a 
high OR when other risk factors are also included. As far as we know, this is the first paper describing the values 
of CypC and its proposed usefulness as CAD marker. The capability of CypC to diagnose CAD presence was also 
showed through the ROC curve. The C-statistic value in this case was 0.89, meaning that if CypC values are high 
then there is a probability of 89% of developing CAD.
Moreover, traditional cardiovascular risk factors frequency (hypertension, dyslipidemia, smoking and age 
>50) is related to higher levels of CypA and CypC, whereas CypB levels are only related to hypertension and 
gender. The relationship of CypA and these parameters was already described, however this is the first study 
where human serum CypB and C levels are analyzed and related to CAD risk21. These results point again to the 
relevance of Cyps in CAD.
CypD has a key role regulating mitochondria function (opening the mPTP), mitochondria-dependent cell 
death, ischemia-reperfusion injury, and it has been also associated with atherosclerosis and diabetes10,31. The inhi-
bition of CypD is postulated as a therapeutic strategy for cardio-protection in ischemia-reperfusion damage31,32. 
All these studies are based on the effect of CypD at mitochondrial level but no data about serum levels of this 
protein are available. In this paper we describe serum levels of CypD that although not significant, probably due 
to the population size, seems to be different depending or not on the presence or absence of the disease. Although 
the relevance of these data is unknown, it is worth mentioning that CypD can be quantified in serum levels and 
the profile in healthy subjects and patients is not the same. Further studies should be done to clarify these findings 
that cannot yet be explained.
The general link between Cyps levels and biochemical blood parameters and cells count require further spe-
cific studies to be understood. However, since many of them are significantly related to the presence of CAD, their 
correlation with CypA and CypC again reinforce the possible engagement of these inmunophilins in this process.
Several limitations should be considered in the present study. First the number of subjects involved in this 
study is relatively small, however it is representative of the number of cases of the health area. The same hap-
pens with gender and age of patients. It is well known that CAD diseases prevalence is higher in men and aging 
people2. However, to avoid bias in control subjects values a wide range of age in men and women were selected, 
although a further analysis should be done in a large population. Second, CypA plasma levels were before pro-
posed as CAD biomarker and related with several pathological process9,21. In addition, CypB was recently related 
Figure 6. Receiver-operating-characteristic curves (ROC) describing the diagnostic performance of 
cyclophilins to identify coronary artery disease (CAD) > 50% as compared with the control subjects. (A) 
Cyclophilin A (CypA), the AUC (c-statistic) was 0.748 (95% confidence interval (CI), 0.654–0.851, p < 0.001). 
(B) Cyclophilin B (CypB), the AUC (c-statistic) was 0.655 (95% CI, 0.538–0.773, p = 0.014). (C) Cyclophilin C 
(CypC), the AUC (c-statistic) was 0.891 (95% CI, 0.821–0.961, p < 0.001), Specificity (88.6%), Sensitivity (70%), 
positive predictive value (VPP) (84.8%) and negative predictive value (VPN) (76%). (D) Cyclophilin D (CypD) 
the AUC (c-statistic) was 0.526 (95% CI, 0.396–0.655, p = 0.687). N = 84.
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with metabolic syndrome13. However, CypC levels were not before studied. Third, total cholesterol and LDL 
values are higher in control subjects than in CAD patients due to antilipidemic treatments. Finally, DM was not 
considered as cardiovascular risk factor because of the limited number of control participants with this medical 
status, this will be considered in further studied. In addition, the intra and inter-assay coefficients of variation of 
the ELISA kits for Cyps determinations were <10%.
In summary, atherosclerosis is a vascular inflammatory disease, which involves several causative agents 
as oxidative stress among others. Migrating inflammatory cells produce large amounts of ROS and other 
pro-inflammatory stimuli that promote cardiovascular diseases. CypA has a key role in ROS production, as chem-
otactic agent and has been extensively associated to these diseases14,19. Since CypB and CypC are associated to 
redox regulation, their participation in those processes could be hypothesized.
Despite study limitations such as a study population relatively small, serum levels of CypC are clearly and sig-
nificantly related with CAD. Further analysis in larger population would clarify the role of this protein. This paper 
describes for the first time that CypC levels are increased in CAD patients and confirms the role of CypA in this 
process. Among them, CypC serum levels highlight as a promising biomarker of CAD.
Material and Methods
Chemicals and solutions. Human Cyclophilin A ELISA kit (CSB-E09920H), Human Cyclophilin B 
ELISA kit (CSB-E11218H) and Human Cyclophilin C ELISA kit (CSB-EL018473HU) were obtained by Cusabio. 
Human Cyclophilin D ELISA kit (E-EL-H1936) was from Elabscience. Human High Sensitivity T Cell Magnetic 
Bead Panel Milliplex® map kit (#HSTCMAG-28SK; #HSTCMAG28SPMX13; #HSTCMAG28SOMX21; 
#HSTCMAG28PMX13BK and #HSTCMAG28PMX21BK) and Human MPP Magnetic Bead Panel 2 Milliplex® 
map kit (#HMMP2MAG-55K) were purchased from Merk (Madrid, Spain).
population study. An observational study about serum levels of Cyps was conducted in patients with symp-
toms of CAD referred to the Cardiology Department of Hospital Universitario Lucus Augusti in Lugo, Spain, 
from January 2017 to March 2018. A total of 40 patients with CAD were included. CAD disease was defined as 
prior myocardial infarction (MI), coronary revascularization or angiographic documentation of any significant 
coronary stenosis. CAD Patients with unstable angina suffering ischemic chess pain and/or electrocardiography 
abnormalities in the previous 24 hours were selected before receiving treatment. These patients were in the early 
onset of acute coronary syndrome. Coronary angiograms were evaluated by experienced cardiologists, who were 
blinded to the patients’ data. A narrowing of artery lumen by more than 51% of the diameter was considered as 
a clinically significant for CAD. Patients with chronic or acute inflammatory disease, rheumatic disease, cancer, 
autoimmune diseases, valvular disease or congestive heart failure were excluded. Also, 44 control subjects with-
out known atherosclerosis disease, with normal angiography findings and normal serum cardiac biomarkers 
were enrolled in the study. All participants included in the present study belong to the public healthcare area of 
Lugo, Spain. The population to be studied was designed according to CAD prevalence in this area. The institu-
tional and regional ethical board (Comité Autonómico de Ética da Investigación de Galicia, Comité Territorial de 
Ética da Investigación de Santiago-Lugo, Secretaria Xeral, Consellería de Sanidade, Xunta de Galicia) approved 
the study (Reference: 2016/508, Approved date: December 19, 2016, according to the principles outlined in the 
Declaration of Helsinki). Participants in the present study were informed and voluntarily written informed con-
sent was obtained from all of them.
Baseline measurements. Information on general vital status and significant clinical data were obtained for 
all the patients and control volunteers from their medical history and personal questionnaires. CAD as well as 
familiar CAD antecedents were recorded. Hypertension (HTA), dyslipidemia (DL), smoking status, age and gen-
der were assessed as cardiovascular risk factors. The lipid-lowering drugs, hypoglycemic drugs and antiagregants 
consumption was also taken into consideration. HTA was considered when blood pressure was ≥140/90 mmHg. 
Univariable analysis Multivariable analysis (1) Multivariable analysis (2) Multivariable analysis (3) Multivariable analysis (4)
OR 95% CI P value OR 95% CI P value OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age > 50 8.18 2.8–23.5 <0.001 5.927 1.2–29.2 0.029 4.208 0.7–22.9 0.097 3.733 0.9–23 0.156 2.455 0.4–15 0.33
Gender (male) 7 2.3–21.1 0.001 10.835 1.2–80.4 0.020 14.064 1.5–130.4 0.02 27.026 2.3–316.5 0.009 18.725 1.8–194.7 0.014
Smoking 8.357 3–22.8 <0.001 14.731 2.8–76.1 0.001 13.499 2.4–74.18 0.003 5.872 0.9–36.4 0.057 4.757 0.8–27.4 0.081
HTA 12.36 3.2–46.5 <0.001 12.714 1.4–109.1 0.020 12.709 1.4–113.2 0.023 22.227 1.8–265.7 0.014 8.989 1.1–70 0.04
DL 13.15 4.4–38.9 <0.001 6.065 1.24–29.6 0.026 5.594 1–30.3 0.046 7.113 1.2–42.7 0.032 5.18 0.9–29.4 0.064
Cyp A > 8.2 ng/
mL 10.11 2.1–48.3 0.004 5.177 0.7–38.2 0.107 4.504 0.5–36 0.156
Cyp C > 17.5 pg/
mL 18.2 5.7–57.5 <0.001 23.002 2.5–209.8 0.005 18.46 2.2–152.6 0.007
Table 4. Correlated Risk factors for coronary artery disease. Analysis was performed on 7 variables: (1) 
Traditional risk factors (age > 50, gender, smoking, HTA and DL), % of cases 88.0, Cox and Snell R2: 0.538, 
Nagelkerke R2: 0.717. (2) Traditional risk factors + CypA, % of cases 86.7, Cox and Snell R2: 0.554, Nagelkerke 
R2: 0.739. (3) Traditional risk factors + CypC, % of cases 88.0, Cox and Snell R2: 0.596, Nagelkerke R2: 0.796. 
(4) Traditional risk factors + CypA + CypC, % of cases 90.4, Cox and Snell R2: 0.605, Nagelkerke R2: 0.807. 
Significant differences p < 0.05. Abbreviations as in Tables 1 and 2.
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Diabetes mellitus (DM) was considered when fasting glucose levels were ≥126 mg/dl or if hypoglicemic treat-
ment or insulin was used. DL was considered if low-density lipoprotein (LDL) cholesterol level was ≥140 mg/
dl or high-density lipoprotein (HDL) cholesterol level was ≤40 mg/dl, or if an antilipidemic treatment was used.
Blood sampling protocol. Peripheral blood was obtained from each participant from the antecubital vein 
using anti-coagulant free tubes (BD vacutainer serum tubes), in the first 24 hours after admission. The blood sam-
ples were allowed to clot for 20 min at room temperature before centrifugation (3,000 rpm for 10 minutes at 4 °C). 
Serum supernatants were collected and stored at −80 °C until needed for analysis. Samples were thawed once.
Measurement of Cyclophilin A, B, C and D serum levels. Levels of serum CypA, CypB, CypC and 
CypD were measured using ELISA regarding manufacturer’s instructions. Before carrying out the experiments, 
serum samples were brought to room temperature, vortexed and centrifuged. Absorbance measurements were 
done in a microplate reader at 450 and 540 nm (only at 450 nm in the case of Cyp D). To correct optical imper-
fections, readings at 540 nm were subtracted from readings at 450 nm. All samples were run by duplicate and 
the concentrations were calculated using a standard curve. The range of determination was 3.12–200 ng/mL for 
CypA; 31.25–2,000 pg/mL for CypB; 23.5–1,500 pg/mL for CypC and 62.5–4,000 pg/mL for Cyp D. Serum levels 
below the lower limit of determination were undetectable and were considered as 0 pg/mL for statistical analysis. 
The intra and inter-assay coefficients of variation of the ELISA kits were <10%. No cross reactivity was observed 
between Cyp antibodies.
Measurement of cytokines and metalloproteinases levels. Levels of serum interferon ϒ (IFNϒ), 
interleukin (IL)-1β, IL-2, IL-6, IL-8, tumor necrosis factor α (TNFα), metalloproteinase (MMP)-2 and MMP-9 
were determined using a magnetic bead-based multiplex immunoassay (Milliplex® Map Kit) according to man-
ufacturer’s instructions. Briefly, the serum was collected and kept at −80 °C until the time of performing the 
ELISA. Before the experiment, the samples were thawed, mixed by vortexing and centrifuged to remove particles. 
Serum samples were diluted (twenty times in the case of cytokines and twice in the case of MMPs) with buffer. 
First, the 96-well filter bottom well was pre-washed. 25 μL of each standard, control or samples were added to 
the appropriate wells with 25 μL of assay buffer provided in the kit and 25 µL of the mixed beads to each well. 
After that, the plate was incubated for 2 hours at room temperature, in the case of cytokines, and for 18 hours 
at 4 °C in the case of MMPs and washed three times with washing buffer. Thereafter, detection antibodies were 
added to each well and incubated for 1 hour at room temperature. The plate was washed as described before and 
Streptavidin-Phycoerythrin added to each well and incubated for 30 min at room temperature. All incubations 
were performed in an orbital shaker at 600 rpm. Finally, the plate was washed, and the median relative fluores-
cence units were recorded using a Luminex® 200™ with xPONENT® software. All samples were run by duplicate 
and the concentrations were calculated using a standard curve. The range of determination was 0.61–2,500 pg/
mL for IFNϒ; 0.49–2,000 pg/mL for IL-1β and IL-2; 0.18–750 pg/mL for IL-6; 0.31–1,250 pg/mL for IL-8; 0.43–
1,750 pg/mL for TNFα; 68–50,000 pg/mL for MMP-2 and 14–10,000 for MMP-9. Serum levels below the lowest 
limit of determination were undetectable and were considered as 0 pg/mL for statistical analysis. There was no 
or negligible cross-reactivity between the antibodies and any of the other analytes. The intra-assay coefficient of 
variation of the ELISA kits were <5%. The inter-assay coefficient of variation of the ELISA kits were <15% (in the 
case of IL-1β, IL-2, IL-8, TNFα and MMP-9) and <20% (in the case of IFNϒ, IL-6 and MMP-2).
statistical analysis. SPSS24 for Windows OS was used for the statistical analysis. Significance was set 
at p < 0.05. Participants were divided in two groups based on CAD diagnosis. Categorical variables were pre-
sented as percentages and continuous variables were presented as means ± SEM. Kolmogorov-Smirnov (with 
Lilliefors correction) was first performed as normality test. Those continuous variables with normal distribution 
were compared using a Student’s T test (including Levene’s test to assess the equality of variance), otherwise 
the non-parametric Mann-Whitney U test was used. In this way, basic characteristics, biochemistry parame-
ters, and levels of Cyps and inflammation markers were compared. Categorical variables were compared using 
Χ2 test. Correlations (bivariate analysis) between Cyps and inflammation markers and blood parameters were 
analyzed using the Spearman rank correlation coefficient. Receiver-operating-characteristic curves (ROC) were 
constructed to assess the sensitivity and specificity of Cyps measurements to know the ability to diagnose CAD 
by means of the area under the curve (AUC) ROC and expressed as C-statistic33,34. In addition, CAD curves were 
used to obtain cut-off points for logistic regression. Specificity, sensitivity, positive predictive value (VPP), neg-
ative predictive value (VPN) and statistic power (P) for the risk score were also calculated. Subsequently, single 
logistic regression model (univariable and multivariable analysis) was used to evaluate the association between 
serum Cyps levels and traditional risk factors (gender, age, smoke, DL and HTA). Data were present following 
STROBE reporting guidelines.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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